Franklin Street Advisors Inc. NC bought a new position in Becton, Dickinson and Company (NYSE:BDX - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 1,414 shares of the medical instruments supplier's stock, valued at approximately $244,000.
Several other institutional investors and hedge funds also recently modified their holdings of BDX. Brighton Jones LLC boosted its position in shares of Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock worth $401,000 after buying an additional 877 shares during the period. NBC Securities Inc. acquired a new position in shares of Becton, Dickinson and Company in the first quarter worth about $102,000. Merit Financial Group LLC lifted its stake in shares of Becton, Dickinson and Company by 54.3% in the first quarter. Merit Financial Group LLC now owns 5,846 shares of the medical instruments supplier's stock worth $1,339,000 after acquiring an additional 2,058 shares in the last quarter. Fermata Advisors LLC acquired a new position in shares of Becton, Dickinson and Company in the first quarter worth about $202,000. Finally, Boltwood Capital Management lifted its stake in shares of Becton, Dickinson and Company by 12.0% in the first quarter. Boltwood Capital Management now owns 1,217 shares of the medical instruments supplier's stock worth $279,000 after acquiring an additional 130 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company's stock.
Insider Buying and Selling
In other news, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the sale, the executive vice president directly owned 4,887 shares in the company, valued at approximately $881,077.23. This represents a 19.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Claire Fraser sold 917 shares of the stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the sale, the director owned 22,226 shares in the company, valued at $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 3,023 shares of company stock worth $562,036 over the last quarter. Insiders own 0.36% of the company's stock.
Wall Street Analyst Weigh In
BDX has been the topic of several recent analyst reports. Weiss Ratings reiterated a "hold (c-)" rating on shares of Becton, Dickinson and Company in a research note on Saturday, September 27th. Argus boosted their price target on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Wall Street Zen upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Wells Fargo & Company boosted their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a research note on Friday, August 8th. Finally, Piper Sandler restated a "neutral" rating and set a $200.00 price objective (up previously from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Three analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company's stock. Based on data from MarketBeat, Becton, Dickinson and Company has an average rating of "Hold" and an average target price of $205.40.
Read Our Latest Report on Becton, Dickinson and Company
Becton, Dickinson and Company Trading Up 1.1%
Shares of NYSE BDX opened at $193.67 on Friday. The stock's 50 day moving average price is $189.03 and its two-hundred day moving average price is $187.68. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99. The stock has a market capitalization of $55.51 billion, a P/E ratio of 34.83, a PEG ratio of 1.50 and a beta of 0.25. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, topping analysts' consensus estimates of $3.40 by $0.28. The business had revenue of $5.51 billion for the quarter, compared to analysts' expectations of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The business's quarterly revenue was up 10.4% on a year-over-year basis. During the same period in the prior year, the firm earned $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.
Becton, Dickinson and Company Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th were given a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date was Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio is presently 74.82%.
About Becton, Dickinson and Company
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Featured Stories
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
